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Abstract
Introduction: ICU-acquired muscle weakness commonly occurs in patients with septic shock and is associated
with poor outcome. Although atrophy is known to be involved, it is unclear whether ligands in plasma from these
patients are responsible for initiating degradation of muscle proteins. The aim of the present study was to
investigate if plasma from septic shock patients induces skeletal muscle atrophy and to examine the time course of
plasma-induced muscle atrophy during ICU stay.
Methods: Plasma was derived from septic shock patients within 24 hours after hospital admission (n = 21) and
healthy controls (n = 12). From nine patients with septic shock plasma was additionally derived at two, five and
seven days after ICU admission. These plasma samples were added to skeletal myotubes, cultured from murine
myoblasts. After incubation for 24 hours, myotubes were harvested and analyzed on myosin content, mRNA
expression of E3-ligase and Nuclear Factor Kappa B (NFB) activity. Plasma samples were analyzed on cytokine
concentrations.
Results: Myosin content was approximately 25% lower in myotubes exposed to plasma from septic shock patients
than in myotubes exposed to plasma from controls (P < 0.01). Furthermore, patient plasma increased expression of
E3-ligases Muscle RING Finger protein-1 (MuRF-1) and Muscle Atrophy F-box protein (MAFbx) (P < 0.01), enhanced
NFB activity (P < 0.05) and elevated levels of ubiquitinated myosin in myotubes. Myosin loss was significantly
associated with elevated plasma levels of interleukin (IL)-6 in septic shock patients (P < 0.001). Addition of antiIL-6
to septic shock plasma diminished the loss of myosin in exposed myotubes by approximately 25% (P < 0.05).
Patient plasma obtained later during ICU stay did not significantly reduce myosin content compared to controls.
Conclusions: Plasma from patients with septic shock induces loss of myosin and activates key regulators of
proteolysis in skeletal myotubes. IL-6 is an important player in sepsis-induced muscle atrophy in this model. The
potential to induce atrophy is strongest in plasma obtained during the early phase of human sepsis.
Introduction
Skeletal muscle weakness frequently develops in patients
admitted to the intensive care unit (ICU), with a
reported incidence between 25% and 60% after more
than one week of mechanical ventilation [1]. ICU-
acquired weakness of the respiratory muscles is asso-
ciated with prolonged weaning and weakness of periph-
eral muscles is associated with prolonged rehabilitation
[2]. Mortality in patients with ICU-acquired weakness is
higher than in ICU patients without weakness [3]. In
addition, in survivors the consequences of ICU-acquired
muscle weakness may persist for more than one year
after ICU discharge [2]. Besides the devastating physical
and psychological effects to patients and their family,
ICU-acquired weakness has a major economical impact.
Among other factors, sepsis is known to be an impor-
tant predictor for the development of ICU-acquired
muscle weakness [4]. In septic patients, weakness may
originate from any point between the central nervous
system and the contractile proteins (for review [5]). The
effect of sepsis on contractile proteins has received
much attention [6,7]. For instance, Tiao et al. [6] found
that in septic rats, skeletal muscle protein breakdown
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ubiquitin-proteasome pathway. However, it is unknown
whether ligands in human septic plasma can activate the
ubiquitin-proteasome pathway and induce loss of myo-
sin. This is of relevance as it will help to understand the
importance of systemic components compared to intrin-
sic muscle factors, such as disuse, in sepsis-induced
muscle atrophy. Previous studies, indeed, have indicated
that cytokines and bacterial cell wall components induce
muscle proteolysis in sepsis [8,9], but specific pathways
have not been evaluated. Therefore, the objective of the
current study was to investigate whether plasma from
patients with septic shock induces loss of myosin and
whether this is associated with activation of the ubiqui-
tin-proteasome pathway. We exposed non-diseased cul-
tured skeletal muscle to plasma from patients with
septic shock. It was hypothesized that septic plasma
induces loss of muscle proteins in highly differentiated
skeletal muscle cells. In a follow-up study we investi-
gated the time course of the atrophic response induced
by plasma obtained from patients admitted with septic
shock. In addition, we explored the relation between
myosin loss and plasma levels of inflammatory
cytokines.
Materials and methods
Experimental design
Two separate sets of experiments were performed. The
first set of experiments was conducted to establish
whether plasma in the early phase of septic shock induces
muscle proteolysis and atrophy. To this end, cultured ske-
letal muscle myotubes were incubated with either plasma
from patients with septic shock obtained within 24 hours
of ICU admission or plasma from healthy subjects (con-
trols). After 24 hours of exposure to plasma, skeletal myo-
tubes were harvested for biochemical analysis, including
myosin heavy chain content and expression of E3-ligases.
The activity of nuclear factor kappa b (NFB) was mea-
sured after one hour of exposure to plasma.
The second set of experiments was conducted to
investigate if the ability of plasma from septic shock
patients to induce muscle atrophy changes during the
course of ICU admission and if a correlation exists
between inflammatory cytokines and loss of myosin.
Hence, plasma was derived at different time points dur-
ing an ICU stay of patients with a septic shock and the
ability of each plasma sample to induce proteolysis and
atrophy in differentiated muscle cells was examined. In
addition, plasma levels of cytokines were determined at
each time point.
Study population
Twenty-one patients with established septic shock,
according to the 2001 International Sepsis Definitions
Conference [10], were included in the first set of experi-
ments. Blood was withdrawn from the indwelling arter-
ial catheter within 24 hours of ICU admission. In 12
control subjects blood was obtained through
venapuncture.
For the second set of experiments, additional blood
samples were obtained from 9 of the 21 septic shock
patients at Days 2, 5 and 7 of the ICU stay. The institu-
tional review board, the medical ethics committee,
approved the current study and waived the need for
informed consent.
Muscle culture
Muscle cells, C2C12 myoblasts, were cultured into myo-
tubes according to previously described methods [11].
Pilot studies showed stable myosin content in myotubes
that differentiated for seven days and that plasma from
healthy subjects does not affect myosin content in these
myotubes. See Additional file 1 for data and more
details.
Analysis of myosin content
Myosin content in myotubes was determined by Wes-
tern blotting according to previous described methods.
See Additional file 1 for more details.
Analysis of NFB activity
NFB is a ubiquitous transcription factor for a variety of
cytokines. The DNA binding activity of NFB has been
shown to be highest within several hours after exposure
to different stimuli [12,13], which was confirmed by
pilot-experiments in our lab. Therefore, in the current
study NFB activity was measured one hour after incu-
bation of the myotubes with plasma.
NFB DNA binding activity was determined by elec-
trophoretic mobility shift assay (EMSA) conform pre-
viously described methods [14]. See Additional file 1 for
details.
Analysis of E3-ligase mRNA and ubiquitinated myosin
levels
Expression of muscle specific E3-ligases, Muscle RING
Finger protein-1 (MuRF-1) and Muscle Atrophy F-box
protein (MAFbx) and ubiquitination of myosin was ana-
lyzed, conforming to previously described methods [15],
see Additional file 1 for details.
Cytokines
Plasma levels of IL-6, IFN-g,T N F - a and IL-1b were
measured by enzyme-linked immunosorbent assay
(ELISA) (for IL-6, IFN-g and TNF-a ELISA kits from
Sanquin Reagents, Amsterdam, The Netherlands, for IL-
1b Quantikinekit from R&D Systems, Minneapolis, MN,
USA). To further examine the role of IL-6, we first
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to septic shock plasma containing an antibody directed
against human IL-6 (R&D Systems). In addition, we stu-
died myosin content in myotubes exposed to control
plasma containing different concentrations of recombi-
nant human IL-6 (Invitrogen, Carlsbad, CA, USA).
Data analysis
Data are presented as means ± standard deviation. The
statistical significances of differences regarding myosin
content, MuRF-1 and MAFbx expression between myo-
tubes exposed to plasma from controls and patient
plasma were analyzed by performing Student t-tests.
Differences regarding NFB activity and cytokine con-
centrations were statistically tested by performing a
Mann Whitney U test. Sample size calculations for the
follow-up study showed that nine patients should be
sufficient to detect a 25% reduction of myosin content
with a standard deviation of 20%, 80% probability and
an alpha level of 0.05. One-way ANOVA with post-hoc
Bonferroni’s multiple comparison testing was used to
evaluate whether myosin content, MuRF-1 and MAFbx
expression and cytokine levels at each day were statisti-
cally different from control. Repeated measures one-way
ANOVA with post-hoc Bonferroni’s multiple comparison
testing was performed to analyze differences between
Day 0 and subsequent days. The relation between myo-
sin and IL-6 levels was explored using a linear model
estimated by Generalized Least Squares to allow for cor-
relations between the measurements caused by repeat-
edly measuring the same subjects; an unstructured
correlation matrix was used to model this dependence.
Since IL-6 levels were not normally distributed, log
transformation on these values was applied. P-values
below 0.05 were considered significant.
Results
Patient characteristics
Patient characteristics are shown in Table 1. All patients
met septic shock criteria. Thirteen of the 21 patients
received one bolus of 100 mg hydrocortisone before
blood withdrawal. Additional characteristics of patients
included in the second set of experiments are shown in
Additional file 1, Table S1. None of the control subjects
reported any significant past medical history or current
use of prescribed medication.
Effects of early septic shock
Myosin content
Myosin content in skeletal myotubes that were exposed
to plasma from septic shock patients was approximately
25% lower than in myotubes that were exposed to
plasma from controls (P <0 . 0 1 ,F i g u r e1 ) .I na d d i t i o n ,
the representative Western blot (Additional file 1, Figure
S3) shows that tubulin content was not affected by sep-
tic plasma, excluding the involvement of a general pro-
tein loss. Furthermore, it demonstrates that myosin
could not be detected in cell medium (experimental
plasma), also excluding cell lysis (Additional file 1, Fig-
ure S4). Discrimination between patients that did and
did not receive steroids prior to blood withdrawal shows
that plasma samples from both groups induce a signifi-
cant and similar myosin loss in myotubes compared to
controls (Additional file 1, Figure S5).
NFB activity and activation of the ubiquitin-proteasome
pathway
We measured NFB activity as it is a key regulator of
the inflammatory response and increased NFB activity
has been associated with activating the ubiquitin-protea-
some pathway and inducing muscle atrophy [16]. Figure
2A shows that NFB activity is significantly increased
upon exposure to septic plasma (P <0 . 0 5 ) ,s e eA d d i -
tional file 1, Figure S6 for a representative Western blot.
T h eE 3l i g a s e s ,M u R F - 1a n dM A F B xa r ek e yr e g u l a t -
ing enzymes of the proteolytic ubiquitin-proteasome
Table 1 Subject characteristics
Control (n = 12) Septic shock (n = 21)
Age (yrs) 59 ± 3 64 ± 3
Male (%) 75% (9/12) 81% (17/21)
APACHE score NA 21 ± 2
Source of septic shock (%)
Pulmonary 14% (3/21)
Gastrointestinal 38% (8/21)
Pancreatitis NA 10% (2/21)
Urinary tract 5% (1/21)
Miscellaneous 33% (7/21)
Past medical history (%)
COPD 19% (4/21)
Carcinoma NA 38% (8/21)
Auto-immune disease 19% (4/21)
Diabetes 19% (4/21)
Figure 1 Effect of septic shock plasma on myosin content.
Myosin content in myotubes that were either exposed to plasma
from controls (n = 12) or plasma from patients with a septic shock
(n = 21). *P < 0.01 vs. controls.
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were significantly higher in myotubes exposed to septic
plasma (Figure 2B).
Finally, exposure to septic shock plasma increased ubi-
quitination of myosin (P < 0.05, Figure 2A).
Effects of prolonged septic shock
Because the current data demonstrate that plasma from
patients with septic shock induces atrophy at ICU
admission, we performed additional experiments to fol-
low this atrophic response in the course of ICU stay.
Myosin content
Figure 3 shows that plasma of patients with septic shock
induced the strongest atrophic response at the first day
of ICU admission. Exposure of myotubes to plasma
obtained at Day 2 and Day 5 after ICU admission also
resulted in lower reduced myosin content compared to
control, but these differences were borderline statisti-
cally significant (P =0 . 0 8a n dP = 0.05 respectively).
Myosin content in myotubes that were exposed to
plasma obtained after seven days of ICU care was not
significantly different from control (P =0 . 2 8 ) .M y o s i n
content at Day 7 was significantly higher than at Day 0
(P < 0.01).
E3-ligase expression
MAFbx expression was highest in myotubes that were
exposed to plasma taken at the first day of ICU admis-
sion (Figure 4). Plasma taken beyond that day did not
Figure 2 Effect of septic shock on NFkB activity, ubiquitinated
myosin and E3-ligase expression. A) Effect of septic shock plasma
on NFkB activity and ubiquitinated myosin. Nuclear Factor Kappa B
(NFB) activity in myotubes that were exposed for one hour to
either plasma from controls (n = 6) or to plasma from patients with
septic shock (n = 6) and ubiquitinated myosin per total myosin
levels in myotubes after incubation for 24 hours with either plasma
from controls (n = 12) or plasma from patients with septic shock (n
= 12). *P < 0.05 vs. controls. B) Effect of septic shock plasma on E3-
ligase expression. Muscle Atrophy F-box protein (MAFbx) and
Muscle RING Finger protein-1 (MuRF-1) expression in myotubes after
incubation for 24 hours with either plasma from controls (n = 5) or
plasma from patients with septic shock (n = 14). *P < 0.05 vs.
controls.
Figure 3 Effect of septic shock plasma to myosin content
during ICU stay. Myosin content in myotubes that were exposed
for 24 hours to plasma from healthy controls (n = 12) and plasma
derived from patients with septic shock (n = 9) at admission (Day 0)
and two, five and seven days after admission to the intensive care
unit (ICU). *P < 0.05 vs. controls. #P < 0.05 vs. Day 0.
Figure 4 Effect of septic shock plasma on E3-ligase expression
during ICU stay. Muscle Atrophy F-box protein (MAFbx) and
Muscle RING Finger protein-1 (MuRF-1) expression in myotubes that
were exposed for 24 hours to plasma from healthy controls (n = 5)
and plasma derived from patients with septic shock (n = 9) at
admission (Day 0) and two, five and seven days after admission to the
intensive care unit (ICU). *P < 0.01 vs. controls. #P < 0.05 vs. Day 0.
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expression at Day 5 and Day 7 were significantly lower
than at Day 0. In contrast, MuRF-1 expression was
enhanced in myotubes by plasma obtained up to Day 7
after ICU admission (Figure 4).
Cytokines
Since cytokines are known to induce proteolysis in mus-
cle cells, we measured IL-1b,I L - 6 ,I F N - g and TNF-a
levels in the plasma samples that were used in the
experiments described above. Upon admission to the
ICU, IL-6 levels were approximately 50-fold higher in
plasma from patients with septic shock compared to
controls (P < 0.001, Figure 5). Although IL-6 levels
decreased rapidly during hospitalization, levels at Days
2, 5 and 7 were still approximately 10-fold higher than
in controls (P = 0.05, P =0 . 0 9a n dP = 0.10 respec-
tively), but significantly lower than at Day 0 (P < 0.01).
Correlation statistics showed a significant negative asso-
ciation between myosin content and plasma IL-6 levels
(P = 0.001, Figure 6).
IFN-g,T N F - a and IL-1b levels were below the detec-
tion limit (respectively 8, 3 and 8 pg/ml) for all controls
and for seven of nine patients with septic shock.
As these data suggest a causative role of plasma IL-6
in inducing muscle atrophy during septic shock, we per-
formed two additional experiments. First, we examined
the effect of blocking IL-6 in septic shock plasma on the
atrophic response of skeletal myotubes. Figure 7A
demonstrates that the addition of anti-IL-6 (100 ng/ml)
to plasma from septic shock patients results in an
approximately 25% higher myosin content in skeletal
myotubes, see Additional file 1, Figure S7 for a repre-
sentative Western blot. In addition, we examined the
effect of elevated IL-6 concentration in plasma from
controls on the atrophic response of skeletal myotubes.
Figure 7B shows that addition of physiological IL-6 con-
centrations (that is, 200 and 600 pg/ml, the mean IL-6
plasma levels in septic patients at respectively Day 2 and
Day 0) and supra-physiological (50 ng/ml) concentra-
tions of IL-6 to plasma from controls did not induce an
atrophic response in skeletal myotubes, see Additional
file 1, Figure S8 for a representative Western blot.
Figure 6 Relation between IL-6 plasma levels and sepsis
induced myosin loss. Correlation between plasma Interleukin-6 (IL-
6) levels and myosin content in myotubes exposed to plasma from
septic shock patients. Log: common logarithm.
Figure 5 Effect of septic shock on plasma IL-6 levels during
ICU stay. Interleukin-6 (IL-6) levels in plasma from controls (n = 9)
and from patients with septic shock (n = 9) taken at admission (Day
0) and two, five and seven days after admission to intensive care
unit (ICU). *P < 0.01 vs. controls. #P < 0.05 vs. Day 0.
Figure 7 Effect of anti-IL6 on sepsis induced myosin loss and
recombinant IL-6 on myosin content. A) Effect of anti-IL6 on
sepsis induced myosin loss. Myosin content in myotubes that were
exposed to plasma from septic shock patients (n = 10), with and
without addition of anti-interleukin-6 (a-IL-6, 100 ng/ml). * P < 0.05.
B) Effect of recombinant IL-6 on myosin content. Myosin content in
myotubes that were exposed to plasma from controls (n = 10) with
addition of IL-6 in different concentrations.
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The present study is the first to demonstrate that (1)
plasma from patients with septic shock induces loss of
myosin and activation of the ubiquitin-proteasome path-
way and (2) that the atrophic response initiated by
plasma from septic shock patients is most severe imme-
diately upon arrival at the ICU and decreases during
subsequent days and (3) IL-6 plays a prominent role in
inducing the atrophic response.
Study limitations
The use of cultured C2C12 skeletal myotubes in the
current study is highly appropriate to specifically study
the contribution of plasma ligands in muscle wasting,
since the use of non-diseased muscle tissue virtually
excludes any contribution of intrinsic muscle abnorm-
alities. Other in vitro models have been used pre-
viously by others, including dissected muscle bundles
[8,18]. A disadvantage of this latter model is the
absence of muscular microcirculation. This induces
oxidative stress and limits the supply of ligands to the
muscle bundle [19,20]. This may explain why incuba-
tion with non-septic human plasma also increased pro-
tein degradation in these models [8]. Therefore, we
considered that model not suitable for the current
research questions.
C2C12 skeletal myotubes reach a considerable degree
of differentiation, as indicated by expression of fast
twitch skeletal muscle troponin T, alpha-actin and tro-
pomyosin [21]. Permeabilized myotubes generate force
when perfused with calcium solutions, with a similar
calcium sensitivity of force generation compared to
mature skeletal muscle fibers [21]. Nevertheless, data
from our own lab [11] and others [22,23] demonstrated
differences in some physiological processes compared to
mature skeletal muscle, such as intracellular calcium
handling. Accordingly, C2C12 cultured myotubes are
suitable for addressing specific research questions, but
limitations should be recognized.
Induction of muscle atrophy in septic shock
Sepsis affects skeletal muscle physiology at different
stages of excitation-contraction coupling, including con-
tractile protein function, muscle protein content (atro-
phy), membrane excitability and mitochondrial function
[24]. We found that myosin content is reduced by
approximately 25% after exposure of muscle to plasma
from patients with septic shock. These data are in line
with previous studies on rodents, showing a rapid loss
of muscle mass upon induction of sepsis [6,25,26]. The
triggers that activate muscle proteolysis in early septic
shock are largely unknown. Observational studies have
proposed several risk factors, including cytokines, corti-
costeroids, hyperglycemia and immobilization [1]. Yet,
as their effects intermingle in vivo, it is very difficult to
establish which of these risk factors do play a role in
skeletal muscle wasting in critically ill patients. By speci-
fically studying the potency of plasma to induce muscle
wasting, the current study demonstrates that plasma
ligands play a prominent role in inducing muscle pro-
teolysis in patients with septic shock. A previous study
found that serum of critically ill patients affect mem-
brane excitability and the excitation-contraction cou-
pling process of isolated muscle fibers [27]. Altogether
these findings indicate that circulating factors contribute
to the development of muscle weakness in critically ill
patients.
We demonstrated that the atrophic response to
plasma obtained beyond the day of ICU admission was
less prominent, but still present. These findings under-
score the necessity of early interventions in the preven-
tion of muscle atrophy in septic shock patients. Since
the set-up in the current study specifically addresses the
effect of plasma ligands, we do not exclude that other
factors, such as immobilization [28] and production of
inflammatory mediators by the muscle itself [29,30] also
contribute to muscle wasting in septic patients, in parti-
cular during prolonged ICU stay.
Circulating ligands
An important question is which plasma factors in septic
shock patients initiate muscle atrophy. First, inflamma-
tory cytokines such as IL-6, TNF-alpha, IL-1-beta and
IFN-g are often implicated in muscle wasting diseases.
In our study, the latter three cytokines were below the
detection limit in all healthy subjects and the majority
of the septic shock patients, suggesting that these were
not a major factor in the development of atrophy in our
model. Plasma IL-6 levels were elevated in patients with
septic shock and plasma levels significantly correlated
with the severity of myosin loss. Moreover, blocking IL-
6i np l a s m af r o ms e p t i cs h o c kpatients diminished the
atrophic response in skeletal myotubes. These data indi-
cate a prominent role of IL-6 in inducing muscle atro-
phy during septic shock. Noteworthy, the addition of IL-
6 to plasma from controls did not induce atrophy of
skeletal myotubes, even when a supra-physiological IL-6
concentration of 50 ng/ml was applied. Thus, while IL-6
in plasma from septic shock patients is important to
induce severe muscle atrophy, other plasma factors
seem to be needed as well. Second, hyperglycemia has
been associated with muscle wasting in critically ill
patients [31] and hyperglycemia induces protein degra-
dation in cultured muscle [32]. Yet, patients in the cur-
rent study were normoglycemic (average glucose level
6.8 ± 0.9 mM), as strict glucose control is part of our
routine clinical care. Accordingly, it is unlikely that
hyperglycemia did directly contribute to muscle wasting
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have been associated with the development of muscle
atrophy [33], although this has been challenged in
recent clinical studies [34]. Nevertheless, the last bolus
of rocuronium was administered more than four hours
before blood withdrawal, ruling out an effect of rocuro-
nium in muscle wasting in our study. Fourth, high doses
of corticosteroids have been associated with skeletal
muscle wasting [35]. In the current study, 13 out of 21
patients received low dose (maximal one bolus of 100
mg i.v.) hydrocortisone prior to blood withdrawal. No
significant difference in atrophy response at Day 1 was
observed between patients that had received hydrocorti-
sone and steroid naive patients (Figure 3C). Moreover,
a tt h et i m em o r ep a t i e n t sh a dr e c e i v e dh y d r o c o r t i s o n e
(Day 2 to Day 7) the atrophic response was lower than
on Day 1. Plasma cortisol concentrations in five of the
studied septic shock patients were above normal levels
(150 to 700 nM). Yet, these plasma samples provoked
similar reductions of myosin in myotubes as plasma
samples with normal cortisol levels (data not shown).
Finally, metabolic acidosis is known to induce muscle
proteolysis by a glucocorticoid-dependent mechanism
[36]. Although plasma pH in most patients was acidic,
there was no significant relation between plasma pH
and myosin concentration (data not shown).
Intracellular mechanisms
The main focus of this study was to investigate whether
myosin loss is triggered by plasma from patients with
septic shock, but we also studied activation of proteoly-
sis in these skeletal myotubes. The ubiquitin-proteasome
pathway is the main proteolytic system in eukaryotic
cells and controls both protein quality and quantity [37].
During the course of this pathway proteins are linked to
a chain of ubiquitin molecules under regulation of E3-
ligases such as MuRF-1 and MAFBx and, subsequently,
recognized and degraded by the proteasome. Recent evi-
dence from our lab indicates that myosin degradation
follows this pathway, as proteasome inhibition restores
myosin content and muscle function in animal models
for respiratory muscle weakness [15]. Moreover, compo-
nents of the ubiquitin-proteasome pathway are up-regu-
lated in skeletal muscle of septic shock patients [38,39].
The current study adds to these earlier observations as
we show that plasma from septic shock patients
increases ubiquitinated myosin levels and activates
MuRF-1 and MAFBx in skeletal myotubes. MuRF-1 has
been shown to specifically ubiquitinate myosin, thereby
promoting myosin degradation [40,41]. MuRF-1 expres-
sion is under control of the transcription factor NFB
[42]. Indeed, exposure to patient plasma increases the
activity of NFB in myotubes within one hour. MAFbx
expression occurs independent from NFB activity, but
is also associated with loss of muscle proteins [43].
Noticeably, in mice overexpression of circulating IL-6
enhances MAFbx mRNA and induces loss of muscle
mass [44]. In line with that study, we found that MAFbx
expression diminished after Day 2 on the ICU and fol-
lowed a similar trend as IL-6, which in turn is inversely
related to myosin content. Therefore, these data further
support the notion that IL-6 is involved in the initiation
of skeletal muscle atrophy in septic shock patients.
Conclusions
The present study demonstrates that plasma from
patients with septic shock induces loss of the contractile
p r o t e i nm y o s i ni ns k e l e t a lm y o t u b e s .T h i sa t r o p h i c
response is most severe to plasma from the early phase
of sepsis and is associated with activation of key regula-
tors of proteolysis. IL-6 may play a role in the early
development of muscle atrophy in septic shock patients.
Key messages
￿ Plasma from patients with septic shock induces
loss of the contractile protein myosin in non-dis-
eased muscle
￿ Plasma-induced myosin loss is most severe in the
early phase of sepsis and is associated with activation
of key regulators of proteolysis
￿ IL-6 may play a role in the early development of
muscle atrophy in septic shock patients
Additional material
Additional file 1: Online supplement. The online supplement to this
manuscript contains detailed methods descriptions, additional data and
pictures of representative Western blots.
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